From: George, Verne [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=8D8C394177AF44B28B4CE452BCCBC851-GEORGE, VERNE]

**Sent**: 11/16/2017 2:13:42 PM

To: Miles, James [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=6c27d6e7b72e48508ef8ae5768ccaad3-JMiles]

CC: Garvey, Mark [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=dcb64df923844466acac67c1f19eabe0-Mgarvey]; Kemker, Carol

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=765ad99166db4233bd15febf6e9917b3-Kemker, Carol]; Banister, Beverly

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=1d7573525c894f5dbfc19abd6a7fda91-Banister, Beverly]; Bookman, Robert

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=1e8db468531a44949eec31f94db4f002-Bookman, Robert]; Toney, Anthony

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=b977b6c39557465c8e1840a451687ae4-Toney, Anthony]; Bates, Keith

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=19222721f29b4d969d4f94c22a24a2a7-Bates, Keith]; Timsina, Gopal

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=9f7677a9d23c44c9b6172dfd8331d5be-Timsina, Go]; Devkota, Om

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=0371347faa7f4cdb93cabc8b3b5fbd51-Devkota, Om]; Spann, Tony

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=57cede00100b4440b9e7c0a86eabfc48-Spann, Tony]; George, Verne

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=8d8c394177af44b28b4ce452bccbc851-George, Verne]; Tucker, Marlene

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=e3e98fdff54241c1b2badc0d1f1b893d-Tucker, Marlene]

Subject: Chemours Update

Attachments: Updates 11.07.2017.docx

## Good Morning James:

As a follow up to my conversation with Robert, attached is the latest update for Chemours.